| 前收市價 | 331.00 |
| 開市 | 330.40 |
| 買盤 | 328.70 x 無 |
| 賣出價 | 328.80 x 無 |
| 今日波幅 | 326.10 - 330.42 |
| 52 週波幅 | 306.80 - 350.50 |
| 成交量 | |
| 平均成交量 | 26,086,705 |
| 市值 | 30.027B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 29.89 |
| 每股盈利 (最近 12 個月) | 0.11 |
| 業績公佈日 | 2024年8月01日 - 2024年8月15日 |
| 遠期股息及收益率 | 0.06 (1.77%) |
| 除息日 | 2024年3月14日 |
| 1 年預測目標價 | 364.20 |
- Reuters
UPDATE 2-Sensodyne-maker Haleon posts tepid sales as demand for some products cool off
Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year. The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth.
ReutersSensodyne-maker Haleon posts tepid sales as demand for some products cool off
The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth. On a reported basis, revenue was down 2.2% on last year.
ZacksPharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
